XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings (Accumulated Deficit) [Member]
Accumulated Other Comprehensive (Loss) [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2023 $ 8,126 $ 57 $ 27,807 $ (13,534) $ (2,697) $ (4,128) $ 7,506 $ 620
Beginning balance, shares at Dec. 31, 2023   1,227            
Net income (loss) (419)     (139)     (139) (280)
Net income (loss) (139)              
Other comprehensive income (loss) (117)       (75)   (75) (42)
Other comprehensive income (loss) [1]         (78)      
Issuance of Shares, value 1 $ 1         1  
Issuance of Shares, shares   11            
Stock-based compensation expense 28   28       28  
Proceeds from exercise of options 6   6       6  
Dividend to non-controlling interests [2] (18)             (18)
Purchase of shares from redeemable non-controlling interests [3] (64)   (45)   (3)   (48) (16)
Ending balance at Mar. 31, 2024 7,543 $ 58 27,796 (13,673) (2,775) (4,128) 7,279 265
Ending balance, shares at Mar. 31, 2024   1,238            
Beginning balance at Dec. 31, 2024 5,380 $ 58 27,764 (15,173) (3,148) (4,128) 5,373 7
Beginning balance, shares at Dec. 31, 2024   1,240            
Net income (loss) 220              
Net income (loss) 214     214     214  
Other comprehensive income (loss) 500              
Other comprehensive income (loss) 473       473 [1]   473  
Issuance of Shares, shares   13            
Stock-based compensation expense 34   34       34  
Proceeds from exercise of options 3   3       3  
Purchase of shares from redeemable non-controlling interests (38)              
Purchase of shares from redeemable non-controlling interests [4] 165   165       165  
Ending balance at Mar. 31, 2025 $ 6,269 $ 58 $ 27,965 $ (14,958) $ (2,675) $ (4,128) $ 6,262 $ 7
Ending balance, shares at Mar. 31, 2025   1,253            
[1] Amounts do not include a $42 million loss from foreign currency translation adjustments attributable to non-controlling interests.
[2] In connection with the dividend to non-controlling interest in Teva’s business venture in Japan.
[3] Purchase of shares from non-controlling interests in Teva’s subsidiary in Switzerland.
[4] In connection with the sale of Teva’s business venture in Japan. See note 17.